GLOBE registry to develop severity, quality-of-life, and cost tools for people with BMI over 25
Official title: Global Overweight and oBesE (GLOBE) Patient Registry, Development and Implementation of Disease-specific: Severity, Quality of Life and Cost Instruments.
Run by Medialis Ltd. · NCT07229027 · Data updated 2026-11-12
This project will create tools to measure severity, quality of life, and the costs of living with a BMI over 25 using input from adults and clinicians.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Medialis Ltd. Industry-sponsored |
| Locations | 1 site (Milton Keynes) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | July 2026 |
| Study ends | August 2026 |
| Registry record updated | November 14, 2025 |
| Trial ID | NCT07229027 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with a self-reported BMI over 25 who can read and complete English-language surveys, are willing to participate, and are not receiving GLP-1 therapy.
✕Probably not a fit
People who cannot provide informed consent, have severe comorbidities that limit participation, cannot read English, or are currently on GLP-1 therapy are unlikely to benefit from or be eligible for this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry will collect data from adults with a BMI over 25 and from healthcare professionals using online surveys and targeted qualitative feedback. It will capture symptoms, comorbidities, health-related quality of life, and direct and indirect costs across the full BMI spectrum while excluding participants on GLP-1 therapy. Clinician and patient perspectives will be integrated through mixed methods to develop disease-specific severity staging, a QoL instrument, and a comprehensive cost checklist. The resulting instruments aim to support earlier identification of needs and more inclusive outcome measurement.
Why it matters
Potential benefit: If successful, these tools could help clinicians and policymakers identify needs earlier, tailor care, and better capture the economic and quality-of-life burden for people with BMI over 25.
How similar studies have gone: While instruments and registries exist for obesity (BMI ≥30) and for patients receiving surgical or pharmacologic treatments, a comprehensive overweight-focused tool that integrates clinical, psychosocial, and cost data is largely novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Patient group
1. Patient is aged ≥18 years at the time of survey completion.
2. Patient has a BMI over 25 (self-reported)
3. Patient is willing to participate in all study activities.
4. Patient is able to read, write, and converse in English.
* Healthcare professional participant must meet the following criteria for inclusion in the study:
1. HCP is aged ≥18 years at the time of survey completion.
2. HCP is suitably qualified and involved in the healthcare management of patients with a BMI over 25
3. HCP is willing to participate in all study activities.
4. HCP is able to read, write, and converse in English.
Exclusion Criteria:
A participant who meets any of the following criteria will be excluded from the study:
1. Participants do not have the cognitive capacity to provide informed consent.
2. Participants with severe co-morbidity that might affect study participation.
Where it's running
-
Online recruitment
Milton Keynes, United Kingdom Recruiting
Study contacts
- Study coordinator: Omolade Allen, PhD
- Email: omolade@medialis.co.uk
- Phone: +447502228066
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How incretin treatments affect muscle mass and function in people with overweight or obesity
This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.
-
Dose find for remimazolam plus alfentanil for gastroscopy in obese adults
This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.
-
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults
This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.
-
Gut barrier and inflammation after fast-food overfeeding in adults
This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
GLP-1 weight‑loss medicine: finding who will benefit most
This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.